Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2018 Oct 2;13(10):e0205300. doi: 10.1371/journal.pone.0205300

Retraction: Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer

The PLOS ONE Editors
PMCID: PMC6168159  PMID: 30278084

After publication of this article [1], similarities were noted between the following pairs of images in Fig 5C:

  • Second AsPC-1 panel (GEM 20 nmol/L) and first CDF-pre-treated AsPC-1 panel (GEM 0 nmol/L)

  • Fourth and sixth AsPC-1 panels (GEM 40 nmol/L and CDF 6 μmol/L)

  • Fourth and seventh CDF-pre-treated AsPC-1 panels (GEM 40 nmol/L and CDF 8 μmol/L)

Wayne State University investigated this work and confirmed that the three images were duplicated in the indicated figure panels. The institution further noted concerns about record-keeping and data management pertaining to this experiment, including questions as to whether the laboratory records align with experimental details and data reported in the article.

In light of these issues, the PLOS ONE Editors retract this article due to concerns about the reliability of the reported data and the accuracy with which results were reported.

BB agreed with the retraction. SA, DK, SHS, ZW, SB, AA, SP, PAP and FHS did not respond.

Reference

  • 1.Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, et al. (2011) Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer. PLoS ONE 6(3): e17850 10.1371/journal.pone.0017850 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES